BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24061513)

  • 1. GNAS Is frequently mutated in a specific subgroup of intraductal papillary neoplasms of the bile duct.
    Tsai JH; Yuan RH; Chen YL; Liau JY; Jeng YM
    Am J Surg Pathol; 2013 Dec; 37(12):1862-70. PubMed ID: 24061513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
    Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct.
    Sasaki M; Matsubara T; Nitta T; Sato Y; Nakanuma Y
    PLoS One; 2013; 8(12):e81706. PubMed ID: 24312577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNF43 mutation frequently occurs with GNAS mutation and mucin hypersecretion in intraductal papillary neoplasms of the bile duct.
    Tsai JH; Liau JY; Yuan CT; Cheng ML; Yuan RH; Jeng YM
    Histopathology; 2017 Apr; 70(5):756-765. PubMed ID: 27864998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GNAS codon 201 mutations are uncommon in intraductal papillary neoplasms of the bile duct.
    Matthaei H; Wu J; Dal Molin M; Debeljak M; Lingohr P; Katabi N; Klimstra DS; Adsay NV; Eshleman JR; Schulick RD; Kinzler KW; Vogelstein B; Hruban RH; Maitra A
    HPB (Oxford); 2012 Oct; 14(10):677-83. PubMed ID: 22954004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas.
    Hosoda W; Sasaki E; Murakami Y; Yamao K; Shimizu Y; Yatabe Y
    Virchows Arch; 2015 Jun; 466(6):665-74. PubMed ID: 25796395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of clonality of multisegmental main duct intraductal papillary mucinous neoplasms of the pancreas based on GNAS mutation analysis.
    Tamura K; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Ideno N; Aso T; Miyazaki T; Ohuchida K; Takahata S; Ito T; Ushijima Y; Oda Y; Mizumoto K; Tanaka M
    Surgery; 2015 Feb; 157(2):277-84. PubMed ID: 25530484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma.
    Ideno N; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Aso T; Aishima S; Miyasaka Y; Ohuchida K; Ueda J; Takahata S; Oda Y; Mizumoto K; Tanaka M
    Pancreas; 2015 Mar; 44(2):311-20. PubMed ID: 25479586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
    Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
    J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
    Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
    J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted next-generation sequencing identifies distinct clinicopathologic and molecular entities of intraductal papillary neoplasms of the bile duct.
    Yang CY; Huang WJ; Tsai JH; Cheng A; Chen CC; Hsu HP; Jeng YM
    Mod Pathol; 2019 Nov; 32(11):1637-1645. PubMed ID: 31231124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways.
    Schlitter AM; Born D; Bettstetter M; Specht K; Kim-Fuchs C; Riener MO; Jeliazkova P; Sipos B; Siveke JT; Terris B; Zen Y; Schuster T; Höfler H; Perren A; Klöppel G; Esposito I
    Mod Pathol; 2014 Jan; 27(1):73-86. PubMed ID: 23828315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GNAS and KRAS mutational analyses of intraductal papillary neoplasms of the pancreas and bile duct developing in the same individual: A case report.
    Date K; Ohtsuka T; Fujimoto T; Gotoh Y; Nakashima Y; Kimura H; Matsunaga T; Mori Y; Mochidome N; Miyazaki T; Oda Y; Tanaka M; Nakamura M
    Pancreatology; 2015; 15(6):713-6. PubMed ID: 26506885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
    Molin MD; Matthaei H; Wu J; Blackford A; Debeljak M; Rezaee N; Wolfgang CL; Butturini G; Salvia R; Bassi C; Goggins MG; Kinzler KW; Vogelstein B; Eshleman JR; Hruban RH; Maitra A
    Ann Surg Oncol; 2013 Nov; 20(12):3802-8. PubMed ID: 23846778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
    Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
    Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts.
    Singhi AD; Nikiforova MN; Fasanella KE; McGrath KM; Pai RK; Ohori NP; Bartholow TL; Brand RE; Chennat JS; Lu X; Papachristou GI; Slivka A; Zeh HJ; Zureikat AH; Lee KK; Tsung A; Mantha GS; Khalid A
    Clin Cancer Res; 2014 Aug; 20(16):4381-9. PubMed ID: 24938521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep sequencing of cancer-related genes revealed GNAS mutations to be associated with intraductal papillary mucinous neoplasms and its main pancreatic duct dilation.
    Takano S; Fukasawa M; Maekawa S; Kadokura M; Miura M; Shindo H; Takahashi E; Sato T; Enomoto N
    PLoS One; 2014; 9(6):e98718. PubMed ID: 24897499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical assessment of the GNAS mutation status in patients with intraductal papillary mucinous neoplasm of the pancreas.
    Ohtsuka T; Tomosugi T; Kimura R; Nakamura S; Miyasaka Y; Nakata K; Mori Y; Morita M; Torata N; Shindo K; Ohuchida K; Nakamura M
    Surg Today; 2019 Nov; 49(11):887-893. PubMed ID: 30879148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GNAS but Not Extended RAS Mutations Spectrum are Associated with a Better Prognosis in Intraductal Pancreatic Mucinous Neoplasms.
    Gaujoux S; Parvanescu A; Cesaretti M; Silve C; Bieche I; Rebours V; Lévy P; Sauvanet A; Cros J
    Ann Surg Oncol; 2019 Aug; 26(8):2640-2650. PubMed ID: 31025231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A GNAS mutation found in pancreatic intraductal papillary mucinous neoplasms induces drastic alterations of gene expression profiles with upregulation of mucin genes.
    Komatsu H; Tanji E; Sakata N; Aoki T; Motoi F; Naitoh T; Katayose Y; Egawa S; Unno M; Furukawa T
    PLoS One; 2014; 9(2):e87875. PubMed ID: 24498386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.